Recently, there has been noticeable progress in combining anti-PD-1/anti-CTLA-4 and anti-PD-L1/anti-TIGIT, which have an objective response rate of 30-50% in advanced non-small-cell lung cancer (NSCLC) (6, 7). This evidence concerns the gene TIGIT and non-small cell lung carcinoma.